Clinical Trial Shows Best Outcomes to Date for Older Hodgkin Lymphoma Patients

(September 18, 2018)

Recently published results of a phase 2 clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuximab vedotin given before and after doxorubicin, vinblastine and dacarbazine (AVD) chemotherapy,... Continue Reading


First In Class Immunostimulating Anticancer Agent able to Directly Inhibit Tumor Signaling and Kill Tumor Cells, is in Clinical Trial for Glioblastoma and Melanoma Metastatic to the Brain

(September 13, 2018)

Small molecule lead drug candidate blocks a critical target for tumors and crosses the blood brain barrier; begins first brain cancer patient dosing in clinical trial at MD Anderson Cancer Center HOUSTON, TX – September 13, 2018 – In the ongoing... Continue Reading


Targeted Combination Treatment for Melanoma now Available

(September 10, 2018)

The US Food and Drug Administration (FDA) approved the combination of Bratovi (encorafenib) and Mektovi (binimetinib)for use in patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. About... Continue Reading


AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström’s Macroglobulinemia, a Rare Type of Blood Cancer

(September 4, 2018)

PRESS RELEASE PR Newswire Aug. 27, 2018, 07:00 AM NORTH CHICAGO, Ill., Aug. 27, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved... Continue Reading


Immune-mediated Nephritis Reported to Occur with Tecentriq®

(August 30, 2018)

Immune-mediated Nephritis Reported to Occur with Tecentriq® Enough patients have developed immune-mediated nephritis which has been biopsy-confirmed in many cases that the manufacturer of Tecentriq now considers this to be an important adverse reaction. ... Continue Reading


About The National Ovarian Cancer Coalition

(August 29, 2018)

Where do you go when you’re first delivered the news: “You have cancer”? For many women diagnosed with ovarian cancer, the answer is the National Ovarian Cancer Coalition (NOCC). With more than 80 chapters nationwide, a Web site (www.ovarian.org)... Continue Reading


Opdivo® (nivolumab) Approved for Treatment of Small Cell Lung Cancer

(August 23, 2018)

The U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the treatment of metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy.1 About Small... Continue Reading


FDA Approves Lenvatinib for Treatment of Advanced Hepatocellular Cancer

(August 20, 2018)

The U.S. Food and Drug Administration (FDA) approved the kinase inhibitor LENVIMA® (lenvatinib) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). This approval was based on results from REFLECT, where LENVIMA... Continue Reading


Melanoma Linked with CLL, Wilmot Recommends Close Monitoring

(August 17, 2018)

While studying a large group of individuals with chronic lymphocytic leukemia (CLL), a Wilmot Cancer Institute scientific team made an important discovery — these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of... Continue Reading


FDA Approves Iobenguane I 131 (Azedra) for Rare Neuroendocrine Tumors

(August 2, 2018)

The US Food and Drug Administration (FDA) today approved Azedra (iobenguane I 131) for the treatment of pheochromocytoma or paraganglioma, which are rare neuroendocrine tumors of the adrenal gland and other tissue areas. About Pheochromocytoma and Paraganglioma Pheochromocytomas... Continue Reading


What is The Optimal Duration of Adjuvant Hormone Therapy for Early Stage Breast Cancer?

(July 25, 2018)

Currently it is recommended that most postmenopausal women with hormone receptor–positive early stage breast cancer be treated with 5 additional years of aromatase inhibitor (AI) therapy following completion of an initial 5 years of treatment. The optimal... Continue Reading


Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation

(July 23, 2018)

Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation... Continue Reading


Next Page »